BC
Broadwood Capital Portfolio holdings
AUM
$1.53B
This Quarter Return
-0.97%
1 Year Return
+36.91%
3 Year Return
+67.63%
5 Year Return
+132.65%
10 Year Return
+697.91%
AUM
$590M
AUM Growth
+$590M
(+0.94%)
Cap. Flow
+$161M
Cap. Flow
% of AUM
27.3%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
9
New
–
Increased
2
Reduced
–
Closed
–
Top Buys
| 1 |
Monster Beverage
MNST
|
$142M |
| 2 |
CYNO
Cynosure, Inc. Class A
CYNO
|
$19.2M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 43.96% |
| 2 | Consumer Staples | 36.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Monster Beverage
MNST
$60.9B
| $213M | 36.06% | 4,797,408 +3,198,272 | +200% | +$142M |
|
2
STAAR Surgical
STAA
$1.36B
| $118M | 19.97% | 10,855,179 | – | – |
|
3
Lineage Cell Therapeutics
LCTX
$267M
| $89.9M | 15.24% | 24,897,032 | – | – |
|
|
CYNO
4
DELISTED
Cynosure, Inc. Class A
CYNO
| $61.1M | 10.35% | 1,338,827 +421,852 | +46% | +$19.2M |
|
5
iShares Russell 2000 ETF
IWM
$67B
| $56.6M | 9.6% | 420,000 | – | – |
|
|
IMDX
6
Insight Molecular Diagnostics Inc. Common Stock
IMDX
$72.4M
| $18.6M | 3.15% | 2,631,680 | – | – |
|
|
AST
7
DELISTED
Asterias Biotherapeutics Inc. Series A
AST
| $17M | 2.89% | 3,699,848 | – | – |
|
|
MNK
8
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $16.1M | 2.72% | 322,411 | – | – |
|
|
AST.WS
9
DELISTED
Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017)
AST.WS
| $179K | 0.03% | 328,205 | – | – |
|